Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Edrecolomab (Panorex), a murine monoclonal antibody targeting the 17-1A cell-surface glycoprotein on epithelial tissues and various carcinomas, exhibits anti-tumor properties and is utilized in colorectal carcinoma research [1] [2].
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | Inquiry | Inquiry | |
5 mg | Inquiry | Inquiry |
Description | Edrecolomab (Panorex), a murine monoclonal antibody targeting the 17-1A cell-surface glycoprotein on epithelial tissues and various carcinomas, exhibits anti-tumor properties and is utilized in colorectal carcinoma research [1] [2]. |
In vitro | Edrecolomab, at concentrations ranging from 0 to 100 μg/mL over a 20-hour duration, exhibits moderate antibody-dependent cellular cytotoxicity (ADCC) [1]. |
In vivo | Edrecolomab administered intravenously at a dosage of 30 μg on days 1, 4, and 7 post-tumor-cell inoculation effectively suppresses tumor development in the HT-29 nude mouse model [1]. |
Synonyms | CO17-1A, Panorex |
Molecular Weight | N/A |
CAS No. | 156586-89-9 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Edrecolomab 156586-89-9 CO17-1A Panorex inhibitor inhibit